|Description||Pharm. for abnormal cell growth|
|Series A, 5/2009 |
ARCH Venture Partners
|Debt, 10/2013 ||$5M|
Lycera isa preclinical-stage biopharma company focused on small molecule immunomodulators for the treatment of rheumatoid arthritis, lupus erythematosis and inflammatory bowel disease Lycera’s first-in-class drugs are designed to treat immune disorders. Lyceraâ€™s technology platforms include proprietary small molecules that modulate a target, which is central to cellular bioenergetics along with molecules that target the Th17 pathway.
Drugs that emerge from the Lycera pipeline will represent first-in-class agents that have the potential for first-in-class oral efficacy without the adverse effects of current standard-of-care antiproliferative and immunosuppressive agents.